Catalyst overview
Research summary
This catalyst tracks a Phase 1b update for Tegoprubart (AT-1501) in Kidney transplantation. The expected timing is based on the latest available company guidance and may change.
8/6/25- Updated data presented. 11/14/25:- Long-term data in 2026. 01/23/26:- 24-month Ph1b kidney transplant data for eight patients presented at ASTS 2026; favorable safety and eGFR. 03/19/26:- 24-month Ph1b kidney extension data reiterated; continued favorable safety and renal function, no acute rejection reported. 05/13/26:- 24-month Ph1b extension data described; additional long-term kidney transplant data from Ph1b expected in 2026. 06/22/26:- Long-term Ph1b kidney transplant follow-up consistent with BESTOW; 16 patients, eight to 24 months. 08/13/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.